Midas Group Inc.(MDS)- NYSE
MDS is defunct.
  • Aug. 28, 2013, 7:37 AM
    • Astex Pharmaceuticals' (ASTX) SGI-110 "showed clear activity in patients with acute myeloid leukemia" in Phase II testing.
    • The overall remission rate in 67 subjects was 25%.
    • However, no results were provided for patients with Myelodysplastic syndromes (MDS), a group of blood and bone marrow disorders, who were also part of the trial.
    • Shares +12.2%.
    | Aug. 28, 2013, 7:37 AM
  • Apr. 19, 2012, 6:54 AM
    S&P names OpenTable (OPEN) and Spectrum Pharmaceuticals (SPPI) as new additions to the S&P SmallCap 600 to replace set-to-be-acquired Zoll Medical (ZOLL) and Midas (MDS).
    | Apr. 19, 2012, 6:54 AM
  • Mar. 13, 2012, 9:00 AM

    Premarket gainers: OMER +31%. MDS +28%. WOLF +26%. UTSI +16%. TTM +3%.
    Losers: SB -10%. COOL -8%. YOKU -5%. URBN -4%. MWE -3%.

    | Mar. 13, 2012, 9:00 AM
  • Mar. 13, 2012, 7:14 AM
    Midas (MDS) agrees to be purchased by TBC Corporation for $11.50 a share in a $310M deal that includes the assumption of $137M worth of the firm's debt and pension liabilities.
    | Mar. 13, 2012, 7:14 AM
  • Mar. 1, 2012, 8:16 AM
    Midas (MDS): Q4 EPS of $0.09 beats by $0.02. Revenue of $43.5M (-6.7% Y/Y) in-line. (PR)
    | Mar. 1, 2012, 8:16 AM
  • Aug. 12, 2011, 8:54 AM

    Midas (MDS) +23.9% premarket after the auto repair and services company announced after yesterday's close that it is exploring strategic alternatives including a possible sale, merger or other business combination.

    | Aug. 12, 2011, 8:54 AM